Recursion announced that the first patient has been dosed in its Phase 2 clinical trial of REC-3964, a potential first-in-class, oral small molecule and new chemical entity for the treatment of recurrent Clostridioides difficile infection. Recursion’s study will initially address the recurrent C. diff. population, which costs the healthcare system approximately two billion dollars per year.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RXRX:
- Cathie Wood’s ARK Investment buys 425K shares of Recursion Pharmaceuticals today
- Cathie Wood’s ARK Investment buys 124K shares of Recursion Pharmaceuticals today
- Recursion Pharmaceuticals’ Groundbreaking Cancer Drug Enters Clinical Trials
- Recursion receives FDA clearance for Phase 1/2 clinical trial of REC-1245
- Cathie Wood’s ARK Investment bought 726.5K shares of Recursion Pharmaceuticals